News
Novo Nordisk issues profit warning
Digest more
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...
The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...
The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected as more "knock-off" weight-loss drugs emerge. Novo Nordisk's share price ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback